Administration
Instructions
Insulin
label must always be checked before each injection to avoid
medication errors between Abasaglar and other insulins.1
The
patient should be advised to read the instructions for use included
in the package leaflet carefully before using Abasaglar.1
Inspect
Abasaglar before use. It must only be used if the solution is clear,
colourless, with no solid particles visible, and if it is of
water-like consistency. 1
Inject
between 1 and 80 units of Abasaglar per injection.2
Abasaglar
is administered subcutaneously into the abdominal area, deltoid or
thigh.1
Injection
sites should always be rotated within the same region in order to
reduce the risk of lipodystrophy and cutaneous amyloidosis.1
Abasaglar
must not be mixed with any other insulin or diluted. Mixing or
diluting can change its time/action profile and mixing can cause
precipitation.2
Abasaglar
should not be administered intravenously.2
Dosing
Instructions
In
patients with T1DM, use Abasaglar concomitantly with mealtime
insulin.3
In
patients with T2DM, Abasaglar can also be given together with OAMs.1
Abasaglar
should be administered once daily at any time but at the same time
each day.1
The
Abasaglar dose regimen (dose and timing) should be individually
adjusted.1
Perform
dosage adjustments of Abasaglar under medical supervision and with
appropriate glucose monitoring.
Dosage
adjustments may be needed with
changes
in physical activity
changes
in meal patterns
episodes
of acute illness, or
changes
in renal or hepatic function.1
References
1.
Abasaglar [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
2.
Abasaglar [instructions for use]. Eli Lilly Nederland B.V., The
Netherlands .
3.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
Abasaglar
= Abasaglar® (insulin glargine) 100 units/mL
OAM
= oral antihyperglycemic medication
T1DM
= type 1 diabetes mellitus
T2DM
= type 2 diabetes mellitus